Literature DB >> 7902235

Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide.

H Nakasa1, M Komiya, S Ohmori, T Rikihisa, M Kitada.   

Abstract

The reductive metabolism of 1,2-benzisoxazole-3-methanesulfonamide (zonisamide) to 2-sulfamoylacetylphenol (SMAP) was observed in liver microsomes from female rats, as well as male rats, but the SMAP-producing activity in female rats was 4-fold lower than that found in male rats. In addition, the reductive metabolism of zonisamide in liver microsomes was induced by the treatment of male rats with phenobarbital. However, the SMAP-producing activity did not correlate positively with the amounts of P-450 2B1 and P-450 2C11 immunochemically determined. In contrast, the reductive metabolism of zonisamide was also found to be induced by the pretreatment of male rats with pregnenolone 16 alpha-carbonitrile, triacetyloleandomycin, and dexamethasone. Furthermore, the SMAP-producing activity correlated highly with the amount of P-450 cross-reactive with antihuman P-450 3A4 antibody, suggesting that P-450 3A1/2 may function in the reductive metabolism of zonisamide. In addition, the P-450 PCNa (3A2) exhibited the SMAP-producing activity in a reconstituted system. The antihuman P-450 3A4 antibody inhibited markedly the formation of SMAP from zonisamide in male rat liver microsomes. These results indicate that cytochrome(s) P-450 belonging to P-450 3A subfamily may be predominantly responsible for the reductive metabolism of zonisamide in rat liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902235

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  2 in total

Review 1.  Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.

Authors:  K Wilbur; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

Review 2.  Interactions between antiepileptic drugs and hormonal contraception.

Authors:  Pamela Crawford
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.